The takeaway
AnaptysBio Inc shows a pronounced seasonal pattern over 9 years of data — strongest in February (+8.2%) and softest in March (−5.4%).
Right now
In July, the stock has risen 56% of years, averaging +1.9% — essentially in line with the S&P 500.
The full picture
AnaptysBio Inc's most dependable month has been February, higher in 7 of 9 years; March has been its least reliable, up just 33% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | ||||||||||||
| 2020 | ||||||||||||
| 2019 | ||||||||||||
| 2018 | ||||||||||||
| 2017 |
Month by month
The stock's clearest edge over the S&P 500 lands in October (+17.4 pts); it has trailed the market most in November (−7.7 pts).
“vs S&P” is AnaptysBio Inc’s average for a month minus the S&P 500’s average for that same month — isolating AnaptysBio Inc’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, February has closed higher 60% of the time versus 78% across the last 9 years — the pattern is weakening.
Figures are the typical (median) February return and how often it rose — the last 5 years versus the last 9(the heatmap’s default window). This verdict stays anchored to that 9-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
This is a stock you can almost set a calendar by, and February is the anchor — it has closed higher in 7 of 9 Februaries, the steadiest beat on its year.
Read it with one caveat: the average (+8.2%) runs well ahead of the median (+1.2%), so a handful of outsized years — not steady strength — do much of the lifting. That reliability comes with real swings, mind — even February ranges by 13.8% from year to year, so any single year can land far from the average. Better still, that strength is the stock's own and not just a buoyant market — February has outpaced the S&P 500 by +8.5 points on average. It is the more striking for the company it keeps — February is a losing month for most of the market, where barely 49% of names gain ground.
It doesn't stand entirely alone — June, October, and December have leaned firm as well, if less emphatically. On the other side of the ledger, March has been the soft spot — the weakest of 3 months that average a loss (−5.4%), and the edge isn't year-round — the stock has trailed the S&P 500 in November, March, and May. Its roughest month on record was a −65.1% November in 2019 — a reminder of how hard even a seasonal name can fall.
The pattern has softened of late, February's last five years slipping below its longer-run record.
For a stock this dependable in February, the sharper question is the rest of the year — outside its strong stretch, the calendar gives far less to lean on. With a short 9-year record and returns that swing hard year to year, the signal is best held loosely.
Short answers on the stock's best month (February), its worst (March), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2017 its best month (February, +8.2%) has run well ahead of its worst (March, −5.4%) — the heatmap above shows how steady that gap has been year to year.
February has been the strongest, averaging +8.2% and closing higher in 7 of 9 years since 2017.
It's the weakest, averaging −5.4% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade